Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stage I Mixed Cell Type Kidney Wilms Tumor 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Intraductal Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Carcinosarcoma 1Burkitt Lymphoma 1Anus Neoplasms 1Anal Canal Carcinoma 1Adenoma, Islet Cell 1

Interventions

Radiotherapy 3Fluorouracil 3Cisplatin 3Nivolumab 2Mitomycin 2X-Rays 1Watchful Waiting 1Taxes 1Specimen Handling 1Sigmoidoscopy 1Radiation 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Immune Checkpoint Inhibitors 1Colonoscopy 1Chemoradiotherapy 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anal Canal Carcinoma × Phantoms, Imaging × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡